Repligen of US to acquire Novozymes Biopharma Sweden

摘要

Denmark's Novo2ymes has agreed to divest Novozymes Biopharma Sweden to American-owned Repligen Corp. "The divestment allows for an even sharper focus on the increasing potential within many of BioBusiness' key focus areas, including hyaluronic acid and Albumin products and technologies for pharmaceutical and medi-cal device applications," the company said in a press statement.Earlier this year, Novozymes announced it has been looking for a potential spin off or divestment of its AMP (antimicrobial peptide) projects.